KMKate Muller

Kate Muller

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kate Muller has a total of 122 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Prevalence of Intestinal Failure-associated Liver Disease (IFALD) in Patients on Long-term Home Parenteral Nutrition

    by Nicholas Wan, Sharifah R. Syed Mustaffa, Andrew Holt, Kate Muller, Jeyamani Ramachandran, Shailesh Bihari, Steven Galluccio, Richard Woodman, Sumudu Narayana, Rachel Wundke, et al.

    Background and Aims: Intestinal failure–associated liver disease (IFALD) is a recognized complication of long-term parenteral nutrition (PN), with reported prevalence ranging from 25–85%, reflecting heterogeneity in patient populations, diagnostic criteria, and PN practices. We aimed to estimate the prevalence of IFALD in Australian adults receiving long-term home-PN (HPN), describe its biochemical and elastographic features, and identify predictors of IFALD. Methods: This was a single-centre, cross-sectional observational study in an Australian tertiary centre. Adults currently receiving long-term HPN (>12 weeks) or had received HPN within the previous decade were included. Patients with malignancy or pre-existing liver disease were excluded. IFALD was defined as persistent, unexplained elevation of liver function tests after exclusion of alternative causes of liver injury. Vibration controlled transient elastography (VCTE) was performed in all patients. Univariate logistic regression was used to evaluate associations between IFALD, nutritional, and biochemical variables. Results: 24 patients were included. The median (inter-quartile range) duration of HPN was 42.5months (15.8-62.3); and weekly calories were 6647 kilocalories (3476.3-8471.3). 15 (62.5%) patients had IFALD. Cholestasis was the predominant biochemical pattern (80%). VCTE demonstrated significant fibrosis (≥ 8 kPa) in 20% and significant steatosis in 40% of IFALD patients. Ongoing HPN was the only variable significantly associated with IFALD on univariate analysis (OR=8, p=0.03). Conclusions: IFALD was highly prevalent and manifested as cholestatic liver injury, with a subset demonstrating elastographic evidence of fibrosis. Ongoing HPN was the main predictor, suggesting potential reversibility with PN cessation. Larger, multicentre studies are needed to identify any clinical predictors of IFALD.

  • Open Access

    The diagnosis and management of portal hypertension in cirrhosis: The Gastroenterological Society of Australia consensus

    by Avik Majumdar, Jacinta Holmes, Stuart K. Roberts, Purnima Bhat, Tim Mitchell, Jeyamani Ramachandran, James O’BEirne, Sarah Walker, Rohit Sawhney, Nishita Jagarlamudi, et al.

    Background: In Australia, chronic liver disease is now the third leading cause of premature death in people aged 50–59 years, and the fourth leading cause in all other 5-year age groups from 35 to 70 years in Australia. A consensus statement on the diagnosis and management of portal hypertension in patients with cirrhosis was developed by the Gastroenterological Society of Australia (GESA), the peak national organization for health care professionals and researchers working in gastroenterology and hepatology, to provide contemporary, evidence-based clinical guidelines. A summary of its recommendations is presented here. Methods: The consensus statement was developed in accordance with the Appraisal of Guidelines for Research and Evaluation II instrument and the 2016 National Health and Medical Research Council Standards for Guidelines. A panel of 46 health care professionals with expertise in managing portal hypertension participated in the development of the consensus statement. The consensus development conference method was used to determine consensus for each recommendation, with a hybrid face-to-face and online meeting held in Noosa, Australia, on 3 August 2024, followed by 2 online meetings. Results: A total of 52 recommendations were approved by the consensus development group without dissent across the following domains: (1) diagnosis, risk stratification, and prevention of decompensation; (2) portal hypertension–related bleeding; (3) ascites and renal impairment; (4) hepatic encephalopathy; (5) sarcopenia, nutrition, and frailty; (6) thrombosis in cirrhosis; (7) cardiopulmonary complications; (8) surgery and portal hypertension; and (9) pregnancy and portal hypertension. Discussion: This is the first Australian consensus statement on the diagnosis and management of portal hypertension in patients with cirrhosis. The recommendations in this summary document provide standardized clinical guidance with the goal of improving outcomes for patients with cirrhosis and portal hypertension in Australia.


  • Open Access

    Protective potential of minimally processed, plant-derived foods against steatotic liver disease in early adulthood

    by Yasmina Tashkent, Jocelyn M. Choo, Steven L. Taylor, Therese A. O'SUllivan, Dujinthan Jayabalan, Sophie J. Miller, Richard Woodman, Luis Calzadilla-Bertot, Oyekoya T. Ayonrinde, Lawrence J. Beilin, et al.

  • The FAITH (Flinders Albumin in the Home) study

    by Kylie Bragg, Rachel Wundke, Jodie Altschwager, Lindsay Moore, Russell Hunt, Sumudu Narayana, Kate Muller, Jeyamani Ramachandran, Alan J Wigg

    Human albumin (HA) infusion has demonstrated benefits for patients with uncomplicated ascites, but implementation of this evidence is limited by critical logistical and budget issues relating to long‐term HA infusion. In this pilot feasibility study of 14 hospital patients with uncomplicated ascites, participants were administered weekly HA by home‐based nursing staff. Results suggest that home‐based HA infusions are safe and feasible, effective and associated with high levels of patient satisfaction and lower relative cost.


  • Open Access

    Home Management of Refractory Ascites in Decompensated Cirrhosis With Long‐Term Abdominal Drains, a Pilot Study

    by Jeyamani Ramachandran, Kylie Bragg, Sumudu Narayana, Jodi Altschwager, Lindsey Moore, Ramon Pathi, Adam Koukourou, Kate Muller, Alan Wigg

  • Top Cited Papers
    Open Access

    COBALT: A Confirmatory Trial of Obeticholic Acid in Primary Biliary Cholangitis With Placebo and External Controls

    by Kris V. Kowdley, Gideon M. Hirschfield, Charles Coombs, Elizabeth S. Malecha, Leona Bessonova, Jing Li, Nuvan Rathnayaka, George Mells, David E. Jones, Palak J. Trivedi, et al.

    INTRODUCTION: Obeticholic acid (OCA) treatment for primary biliary cholangitis (PBC) was conditionally approved in the phase 3 POISE trial. The COBALT confirmatory trial assessed whether clinical outcomes in patients with PBC improve with OCA therapy. METHODS: Patients randomized to OCA (5–10 mg) were compared with placebo (randomized controlled trial [RCT]) or external control (EC). The primary composite endpoint was time to death, liver transplant, model for end-stage liver disease score ≥15, uncontrolled ascites, or hospitalization for hepatic decompensation. A prespecified propensity score–weighted EC group was derived from a US healthcare claims database. RESULTS: In the RCT, the primary endpoint occurred in 28.6% of OCA (n = 168) and 28.9% of placebo patients (n = 166; intent-to-treat analysis hazard ratio [HR] = 1.01, 95% confidence interval = 0.68–1.51), but functional unblinding and crossover to commercial therapy occurred, especially in the placebo arm. Correcting for these using inverse probability of censoring weighting and as-treated analyses shifted the HR to favor OCA. In the EC (n = 1,051), the weighted primary endpoint occurred in 10.1% of OCA and 21.5% of non-OCA patients (HR = 0.39; 95% confidence interval = 0.22–0.69; P = 0.001). No new safety signals were identified in the RCT. DISCUSSION: Functional unblinding and treatment crossover, particularly in the placebo arm, confounded the intent-to-treat estimate of outcomes associated with OCA in the RCT. Comparison with the real-world EC showed that OCA treatment significantly reduced the risk of negative clinical outcomes. These analyses demonstrate the value of EC data in confirmatory trials and suggest that treatment with OCA improves clinical outcomes in patients with PBC.


  • Liver transplantation for acute-on-chronic liver failure due to carnitine palmitoyl transferase (CPT) 1A deficiency

    by Claire L. Smart, Drago Bratkovic, Kate R. Muller

    An abstract is unavailable. This article is available as a PDF only.

  • Treating chronic hepatitis C in general practice

    by Kate Muller, Mohamed Hasan

    Most patients with hepatitis C can be treated in general practice, increasing the number of patients who have access to treatment and reducing the likelihood of progression to advanced liver disease.


  • Cost effectiveness of treatment models of care for hepatitis C: the South Australian state-wide experience

    by Jeyamani Ramachandran, Billingsley Kaambwa, Kate Muller, James Haridy, Edmund Tse, Emma Tilley, Rosalie Altus, Victoria Waddell, David Gordon, David Shaw, et al.

    Aim: The objective was to study the long-term (lifetime) cost effectiveness of four different hepatitis C virus (HCV) treatment models of care (MOC) with directly acting antiviral drugs. Methods: A cohort Markov model-based probabilistic cost-effectiveness analysis (CEA) was undertaken extrapolating to up to 30 years from cost and outcome data collected from a primary study involving a real-life Australian cohort. In this study, noncirrhotic patients treated for HCV from 1 March 2016 to 28 February 2017 at four major public hospitals and liaising sites in South Australia were studied retrospectively. The MOC were classified depending on the person providing patient workup, treatment and monitoring into MOC1 (specialist), MOC2 (mixed specialist and hepatitis nurse), MOC3 (hepatitis nurse) and MOC4 (general practitioner, GP). Incremental costs were estimated from the Medicare perspective. Incremental outcomes were estimated based on the quality-adjusted life years (QALY) gained by achieving a sustained virological response. A cost-effectiveness threshold of Australian dollar 50 000 per QALY gained, the implicit criterion used for assessing the cost-effectiveness of new pharmaceuticals and medical services in Australia was assumed. Net monetary benefit (NMB) estimates based on this threshold were calculated. Results: A total of 1373 patients, 64% males, mean age 50 (SD ±11) years, were studied. In the CEA, MOC4 and MOC2 clearly dominated MOC1 over 30 years with lower costs and higher QALYs. Similarly, NMB was the highest in MOC4, followed by MOC2. Conclusion: Decentralized care using GP and mixed consultant nurse models were cost-effective ways of promoting HCV treatment uptake in the setting of unrestricted access to new antivirals.